Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is more or less 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts price targets range from a high of $101 to a low of $61.
From the newest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The Long or retail Term Care segment has offering of prescription medications and assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products as well as similar services, which includes medical, pharmacy, dental, behavioural health, medical management abilities. The Corporate segment involves in providing administrative services as well as management. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.